IL-27

IL-27 Overview

English NameInterleukin-27Approved Drugs0
Drugs in Clinical Trials1Target SynonymIL27,Interleukin-27,Interleukin 27,IL-27A,IL-27
Highest Development StagePhase 2 Clinical
English NameInterleukin-27
Target SynonymIL27,Interleukin-27,Interleukin 27,IL-27A,IL-27
Approved Drugs0
Drugs in Clinical Trials1
Highest Development StagePhase 2 Clinical

IL-27 Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Mouse (1)Human (3)

  • Tag

    His Tag & Avi Tag (1)Fc Tag (1)Tag Free (1)His Tag (1)

  • Conjugate

    Biotin-labeled (1)Unconjugated (3)

IL-27 Background

Interleukin-27 (IL-27) is a heterodimeric cytokine belonging to the IL-12 family that is composed of two subunits, Epstein-Barr virus (EBV)-induced gene 3 (EBI3) (also known as IL-27B) and IL27-p28 (known as IL-30). IL-27 is produced by antigen-presenting cells. IL-27 plays an important function in regulating the activity of B and T lymphocytes. The effects of IL-27 are eliciting by its interaction with a specific cell surface receptor complex composed of two proteins known as IL27R and gp130. IL-27 is a cytokine with pro- and anti-inflammatory properties, that can regulate T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. IL-27 reveals to be a potent inhibitor of TH17 cell development and of IL-17 production. IL-27 also antagonizes the effects of some cytokines such as IL6 through direct effects on T cells. Another important role of IL-27 is its antitumor activity and antiangiogenic activity.

IL-27 Synonyms

Interleukin-27,IL27A&IL27B,EBI3&p28

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
CasdozokitugSRF-388Phase 2 ClinicalSurface Oncology IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Solid tumours
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland